TITLE: Adenosine A3 antagonists
INVENTOR(S): Sugiura, Yoshihiro; Miwatari, Seiji; Kimura, Hiroyuki; Knzaki, Naoyuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11158073	A	19990615	JP 1998-270755	19980925 <--
PRIORITY APPLN. INFO.:			JP 1997-262525 A	19970926 <--

OTHER SOURCE(S): MARPAT 131:78466
ED Entered STN: 23 Jun 1999
AB Adenosine A3 receptor antagonists contain (un)substituted amino-substituted N2-3-containing heterocyclic [5-8 ring-containing] compds. such as 2-chloro-4-ethylamino-6-phenylamino-1,3,5-triazine and 2,4-bis[phenylamino]-6-cyclohexylamino-1,3,5-triazine. Of 6 compds. tested, the IC50 values of adenosine A3 receptor antagonist activities ranged from 0.7 to 285.9 nM as determined in human adenosine A3 receptor-expressing plasmid-transformed CHO (dhfr-) cell cultures. Tablets were formulated containing 2,4-bis[phenylamino]-6-cyclohexylamino- 1,3,5-triazine 50, lactose 34, corn starch 10.6, corn starch paste 5, magnesium stearate 0.4 and calcium CM-cellulose 20 mg. The drugs are useful for treating e.g. brain ischemic disease.
IC ICM A61K031-535
ICS A61K031-00; A61K031-505; A61K031-53; C07D251-18; C07D251-50; C07D251-70; C07D403-04
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 1973-09-7 6737-62-8 17654-47-6 21665-49-6 50831-60-2 53773-08-3 53773-09-4 53773-10-7 54589-65-0 61038-64-0 101119-13-5 107274-03-3 113696-90-5 156126-89-5 189249-05-6 228574-85-4 228574-86-5 228574-87-6 228574-88-7 228574-89-8 228574-90-1 228574-91-2 228574-92-3 228574-93-4 228574-94-5 228574-95-6 228574-96-7 228574-97-8 228574-98-9 228574-99-0 228575-00-6 228575-01-7 228575-02-8 228575-03-9 228575-04-0 228575-05-1 228575-06-2 228575-07-3 228575-08-4 228575-09-5 228575-10-8 228575-11-9 228575-12-0 228575-13-1 228575-14-2 228575-15-3 228575-16-4 228575-17-5 228575-18-6 228575-19-7 228575-20-0 228575-21-1 228575-22-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A3 receptor antagonists and pharmaceutical compns.)
IT 228575-10-8 228575-13-1 228575-14-2 228575-15-3 228575-16-4 228575-17-5 228575-18-6 228575-19-7 228575-20-0 228575-21-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A3 receptor antagonists and pharmaceutical compns.)
RN 228575-10-8 HCAPLUS
CN 4-Pyrimidinamine, 6-chloro-N,2-diphenyl- (CA INDEX NAME)



RN 228575-13-1 HCAPLUS
CN 4-Pyrimidinamine, N-cyclohexyl-6-hydrazinyl-2-phenyl- (CA INDEX NAME)



RN 228575-14-2 HCAPLUS
CN 4,6-Pyrimidinediamine, N4-cyclohexyl-N6,2-diphenyl- (CA INDEX NAME)



RN 228575-15-3 HCAPLUS
CN 4,6-Pyrimidinediamine, N4,N6,2-triphenyl- (CA INDEX NAME)



RN 228575-16-4 HCAPLUS
CN 4,6-Pyrimidinediamine, N4,2-diphenyl-N6-(phenylmethyl)- (CA INDEX NAME)



RN 228575-17-5 HCAPLUS
CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N,2-diphenyl- (CA INDEX NAME)



RN 228575-18-6 HCAPLUS
CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 228575-19-7 HCAPLUS
CN Pyrimidine, 4-hydrazinyl-6-phenoxy-2-phenyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 228575-20-0 HCAPLUS
CN 4-Pyrimidinamine, 6-phenoxy-N,2-diphenyl- (CA INDEX NAME)



RN 228575-21-1 HCAPLUS
CN 4-Pyrimidinamine, N-cyclohexyl-6-phenoxy-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl